5 news items
Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
ALKS
28 Aug 24
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has
Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2
ALKS
22 Aug 24
Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative
Alkermes plc Reports Second Quarter 2024 Financial Results
ALKS
24 Jul 24
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience
Alkermes to Report Second Quarter Financial Results on July 24, 2024
ALKS
17 Jul 24
plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company
Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024
ALKS
3 Jun 24
that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products
- Prev
- 1
- Next